Toxic Epidermal Necrolysis in Polymedicated Patient Treated With Radiotherapy.
10.4168/aair.2015.7.2.199
- Author:
Remedios PEREZ-CALDERON
1
;
M Angeles GONZALO-GARIJO
;
Silvia CORRALES-VARGAS
;
Gloria JIMENEZ-FERRERA
;
Isabel RODRIGUEZ-NEVADO
;
Mario DIAZ-DELGADO
Author Information
1. Department of Allergology and Clinical Immunology, Infanta Cristina University Hospital, Badajoz, Spain. magonzalog@gmail.com
- Publication Type:Case Report
- Keywords:
Drug hypersensitivity;
radiotherapy;
temozolomide;
toxic epidermal necrolysis;
trimethoprim sulfamethoxazole
- MeSH:
Anticonvulsants;
Chemoradiotherapy;
Codeine;
Dexamethasone;
Drug Hypersensitivity;
Glioblastoma;
Humans;
Omeprazole;
Prognosis;
Radiotherapy*;
Skin;
Stevens-Johnson Syndrome*;
Trimethoprim, Sulfamethoxazole Drug Combination
- From:Allergy, Asthma & Immunology Research
2015;7(2):199-201
- CountryRepublic of Korea
- Language:English
-
Abstract:
Temozolomide is an oral alkylating agent indicated for the treatment of patients with glioblastoma multiforme concomitantly with radiotherapy and subsequently as monotherapy treatment. We report the case of a patient who developed toxic epidermal necrolysis (TEN) while she was being treated with chemoradiotherapy and several drugs. Cutaneous tests were performed with the drugs involved with negative result. Although the occurrence of TEN contraindicates suspected drug readministration, we based the decision to perform the controlled administration of temozolomide on the following reasons: (1) the poor prognosis of the underlying disease, (2) the lack of therapeutic alternatives, (3) the suspicion that other drugs taken by the patient simultaneously may be responsible (as anticonvulsants and trimethoprim sulfamethoxazole [TMP-SMX]), and (4) temozolomide was the first choice for treating the patient's disease. The administration of a cumulative dose of 60 mg of temozolomide caused a slight skin reaction. Given this result, we conducted controlled administration of other drugs involved. Dexamethasone, codeine, omeprazole and levetiracetam were well tolerated. However, TMP-SMX produced a similar reaction to that caused by temozolomide. In conclusion, we present the first case of TEN induced by temozolomide and TMP-SMX associated with cranial radiotherapy confirmed by controlled administration. Radiotherapy in combination with these drugs could have favored TEN, as some authors have postulated, but we cannot prove this.
